Trial Profile
Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E2)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Vicriviroc (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms VICTOR-E2
- Sponsors Merck Sharp & Dohme Corp.
- 10 Sep 2019 Status changed from discontinued to withdrawn prior to enrolment.
- 30 Nov 2006 Status change
- 05 Sep 2006 Status change